| Outcome Measures: |
Primary: Change in glucagon between euglycemia and hypoglycemia, Mean and peak glucagon level during euglycemia and each hypoglycemic period of the clamp, During each clamp, up to 12 weeks | Secondary: Insulin infused, Insulin administered during euglycemia and each hypoglycemic period of the clamp, During each clamp, up to 12 weeks|Insulin infusion rate, Rate of insulin administered during euglycemia and each hypoglycemic period of the clamp, During each clamp, up to 12 weeks|Change in catecholamines between euglycemia and hypoglycemia, Epinephrine and norepinephrine during euglycemia and each stable hypoglycemic period of the clamp, During each clamp, up to 12 weeks|Change in growth hormone between euglycemia and hypoglycemia, Growth hormone during euglycemia and each stable hypoglycemic period, During each clamp, up to 12 weeks|Change in cortisol between euglycemia and hypoglycemia, Cortisol during euglycemia and each stable hypoglycemic period, During each clamp, up to 12 weeks | Other: Symptom score during hypoglycemia, The Edinburgh hypoglycemia symptom score assesses the presence and extent (on a scale of 1, not present to 7, present a great deal) of 16 common symptoms which may be experienced by an individual while their blood glucose is low. The score does not indicate any outcome., During each clamp, up to 12 weeks
|
